MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$202,674K
Unrealized (loss) gain, net
on marketable...
$504K
Net loss
attributable to common...
-$201,917K
(23.68%↑ Y/Y)
Foreign currency
translation adjustment
-$1,261K
Net loss
-$196,539K
(24.58%↑ Y/Y)
Accrued dividends on
convertible preferred stock
$5,378K
(35.47%↑ Y/Y)
US
$133,551K
Non us
$61,220K
(79.96%↑ Y/Y)
Loss before income
taxes
-$196,042K
(24.67%↑ Y/Y)
Provision for income taxes
$497K
(43.64%↑ Y/Y)
Product
$194,771K
Loss from operations
-$192,016K
(27.68%↑ Y/Y)
Total other income
(expense), net
-$4,026K
(-176.73%↓ Y/Y)
Total revenues
$189,757K
(45.83%↑ Y/Y)
Interest income
$15,293K
(3.96%↑ Y/Y)
Other income, net
$1,264K
(-43.55%↓ Y/Y)
License
-$5,014K
Total costs and
expenses
$381,773K
(-3.50%↓ Y/Y)
Interest expense
$20,583K
(-0.10%↓ Y/Y)
Selling, general, and
administrative
$194,941K
(35.09%↑ Y/Y)
Research and development
$167,340K
(-29.68%↓ Y/Y)
Cost of sales
$19,492K
(45.81%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)